ClinicalTrials.Veeva

Menu

Development and Evaluation of a Cognitive Enhancement Product Made From Selected Thai Herbs for Menopausal Women

K

Khon Kaen University

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Dietary Supplement: MP1
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT02567760
HE 571329

Details and patient eligibility

About

This study is set up to determine the cognitive enhancing effect and consumption safety of the novel cognitive enhancement product made from the combined extract of Z. mays (purple color) and P. amaryllifolius based-drink (MP1) in menopausal volunteer.

Full description

Memory impairment is one of the common health problems in menopausal women. Due to the therapeutic efficiency limitation, the searching for the protective intervention for this condition is required. Based on the previous findings that the combined extract of Z. mays (purple color) and P. amaryllifolius based-drink (MP1) could attenuate memory impairment in animal model of menopause, the investigators aimed to investigate the effect of MP1 functional drink on working memory, psychological fitness, possible underlying mechanism and the consumption safety in menopausal volunteers.

Enrollment

30 patients

Sex

Female

Ages

45 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy perimenopausal and postmenopausal women (<5 years menstruation cessation) who live in Northeastern of Thailand.

Exclusion criteria

  • Subject who is diagnosed with one of the following: cardiovascular diseases, respiratory diseases,neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded.
  • Hysterectomy and/or Oophorectomy
  • Subject who use hormone or any drug exerts the influence on Hypothalamic Pituitary Gonadal axis and nervous system.
  • Body mass index >27
  • Athlete or subject who has a regular exercise.
  • Smoker or heavy drinker

Trial design

30 participants in 2 patient groups, including a placebo group

MP1 group
Active Comparator group
Description:
Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
Treatment:
Dietary Supplement: MP1
Placebo group
Placebo Comparator group
Description:
Subject receive the Placebo product for 8 weeks.
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems